- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 3/04 - AnorexiantsAntiobesity agents
Patent holdings for IPC class A61P 3/04
Total number of patents in this class: 7378
10-year publication summary
|
227
|
338
|
441
|
445
|
564
|
538
|
525
|
571
|
634
|
303
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Takeda Pharmaceutical Company Limited | 2718 |
85 |
| Eli Lilly and Company | 4033 |
73 |
| Novo Nordisk A/S | 2299 |
72 |
| Shionogi & Co., Ltd. | 862 |
71 |
| Boehringer Ingelheim International GmbH | 4529 |
59 |
| Pfizer Inc. | 3366 |
54 |
| LG Chem, Ltd. | 17822 |
51 |
| Société des Produits Nestlé S.A. | 9955 |
49 |
| Daiichi Sankyo Company, Limited | 1887 |
44 |
| Nestec S.A. | 2589 |
42 |
| Janssen Pharmaceutica N.V. | 3233 |
42 |
| Taisho Pharmaceutical Co., Ltd. | 860 |
40 |
| Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 858 |
39 |
| The Regents of the University of California | 20534 |
38 |
| Novartis AG | 10346 |
37 |
| Sunshine Lake Pharma Co., Ltd. | 618 |
37 |
| Institut National de La Sante et de La Recherche Medicale (inserm) | 3124 |
32 |
| Ajinomoto Co., Inc. | 2277 |
31 |
| Bristol-myers Squibb Company | 4812 |
29 |
| AstraZeneca AB | 2836 |
29 |
| Other owners | 6424 |